Globin Solutions
Pre-clinical biotech firm leveraging globin chemistry for breakthrough antidotal therapies.
Founded
2017Pre-clinical biotech firm leveraging globin chemistry for breakthrough antidotal therapies.
Globin Solutions, founded with a mission to leverage globin chemistry and protein engineering, aims to develop groundbreaking antidotal therapies for human poisonings. As a pre-clinical biopharmaceutical company, it focuses on creating heme-based solutions to address critical medical needs in the field of toxicology. The company's innovative approach is centered on utilizing advanced biotechnology to engineer effective treatments that can neutralize various toxins and poisons, thereby saving lives and improving patient outcomes.
Notable figures associated with Globin Solutions include experts in biochemistry and pharmacology, though specific names are not publicly highlighted. The company has attracted interest from investors focused on cutting-edge medical technologies. Key achievements include significant advancements in pre-clinical trials and the development of proprietary heme-based therapeutic platforms. Globin Solutions' impact lies in its potential to revolutionize the treatment of poisonings, offering new hope and improved care standards in emergency medicine.
Companies similar to Globin Solutions include Hemoglobin Oxygen Therapeutics, Globavir Biosciences, Ophirex and Hemobiotech.
Globin Solutions was founded in 2017.
Globin Solutions' headquarters is located in Pittsburgh, PA, US.
Globin Solutions' most recent funding round was for $750k (USD) in November 2021.
As of Nov 1, 2021, Globin Solutions has disclosed funding of $7.3M (USD). Undisclosed round amounts are excluded.
Globin Solutions has 8 employees as of Feb 5, 2024.
Hemobiotech
